666 results about "Glycosylation" patented technology

The invention relates to a recombinant expression cat interferon-omega gene and a preparation method and application thereof, the nucleotide sequence of the cat interferon-omega gene is as shown in SEQ ID NO.1, and the cat interferon-omega gene is obtained by introducing an Fc fusion fragment to the C terminal and / or N terminal of the natural gene sequence of the cat interferon-omega. XTEN or PAS is introduced to prolong a peptide fragment, and original glycosylation modification sites on a natural sequence are reserved. The method comprises the following steps: cloning a cat interferon-omega gene into an expression vector containing double promoters, further transfecting into a cell, carrying out stable cloning and screening, establishing a high-expression cell strain, and carrying out fermentation culture in a bioreactor. According to the invention, the cat interferon-omega gene is subjected to multiple modification and is efficiently expressed in a CHO-K1GS system, so that the protein yield, the stability and the half-life period are remarkably improved; the obtained fusion protein is high in purity and strong in activity, can obviously enhance immune response and protection effect when being matched with cat vaccines, and is good in safety.

The invention discloses a preparation method of soybean milk powder for promoting immune regulation, and belongs to the technical field of soybean product processing. Performing biological enzymolysis; modifying soybean protein; compounding functional components; and preparing the microcapsule. An ultrasonic-enzyme composite extraction technology is applied, and the enrichment rate of components with immunocompetence is increased. According to the method, the Maillard reaction is performed on the soybean protein and the polysaccharide by utilizing an ultrasonic-assisted heating technology, so that the emulsifying characteristic of the soybean protein isolate is improved, and the immunoregulation promoting performance of the soybean protein isolate is greatly improved. According to the invention, through a microcapsule embedding technology, glycosylated soybean protein is wrapped in the particles by a wall material formed by galactooligosaccharide and resistant dextrin, the stability and bioavailability are improved, the microencapsulation efficiency is greater than 95%, and the immunoregulation promotion performance of the microencapsulated soybean protein is effectively exerted. By adopting spray drying, inactivation of immune active components caused by high temperature is avoided.

The invention belongs to the technical field of detection and analysis, and provides a method for detecting the average coupling rate of a high-hydrophilicity small-molecule high-glycosylation antibody coupling drug and application of the method for detecting the average coupling rate of the high-hydrophilicity small-molecule high-glycosylation antibody coupling drug. The method comprises the following steps: firstly, carrying out desugaring treatment on a high-glycosylation coupling medicine, then coupling desugarized high-hydrophilicity toxin molecules with an antibody medicine, analyzing by using hydrophilic interaction chromatography conditions, and calculating to obtain the accurate average coupling rate of the antibody coupling medicine. According to the method, through desugaring treatment and hydrophilic interaction chromatography detection in the analysis process, the defect that the separation degree of high-hydrophilicity micromolecules with different coupling ratios is low due to hydrophobicity difference in a traditional method is overcome, so that the measured average coupling rate result is more accurate and real. The method is suitable for coupling a high-hydrophilicity payload drug with a high-glycosylation antibody drug, and is especially suitable for an antibody coupling drug which is high in micromolecule hydrophilicity and has obvious influence on the separation degree of a traditional DAR liquid phase analysis method.

The invention discloses an application of rhamnolactobacilli SSN-13 in preparation of anti-glycosylation and anti-aging drugs, and is characterized in that the preservation number of the rhamnolactobacilli SSN-13 is CGMCC No: 27227, and the application of the rhamnolactobacilli SSN-13 in preparation of preparations for improving degenerative changes of skin, intestinal tracts, liver and brain tissues and cognitive function decline caused by individual aging is provided, and the application of the rhamnolactobacilli SSN-13 in preparation of anti-glycosylation and anti-aging drugs in preparation of anti-glycosylation and anti-aging drugs in preparation of anti-glycosylation and anti-aging drugs in preparation of anti-glycosylation and anti-aging drugs. According to the present invention, the application in the preparation of the preparation for improving the composition and the structure of the aging individual intestinal flora has the advantages of significantly improving the inhibition ability of glycosylation reaction products AGEs, pentosan, fructosamine and dityrosine, reducing the levels of IL-1beta, IL-6, TNF-alpha, 8-OHdG and AGEs in serum, improving the enzymatic activity of SOD and GSH-Px, improving the HA content and the moisture content in skin, reducing the MDA content, and improving the cognitive ability.

The invention relates to an engineered glycosyltransferase and a steviol glycoside glucosylation method. The present invention provides engineered glycosyltransferases (GTs), polypeptides having GT activity and polynucleotides encoding the enzymes, as well as vectors and host cells comprising the polynucleotides and polypeptides. The present invention provides engineered sucrose synthases (SuS), polypeptides having SuS activity and polynucleotides encoding the enzymes, as well as vectors and host cells comprising the polynucleotides and polypeptides. The invention also provides compositions comprising the GT enzymes and methods of using the engineered GT enzymes to prepare products having beta-glucose ligation. The present invention also provides compositions and methods for producing rebaudioside (e.g., rebaudioside M, rebaudioside A, rebaudioside I, and rebaudioside D). The invention also provides compositions comprising the SuS enzymes and methods of using the same. Methods for producing a GT enzyme and a SuS enzyme are also provided.

The present invention belongs to the technical field of genetic engineering. Provided are a single-base editor, a deaminase used therein, and the use thereof. The technical problems to be solved are to identify a naturally occurring cytosine deaminase without sequence preference, construct a base editor, and improve the efficiency and scope of base editing. In order to solve the technical problems above, a cytosine base editor is provided. The cytosine base editor is a fusion protein, wherein the fusion protein is a protein containing a cytidine deaminase, a Cas protein and a uracil-DNA glycosylase inhibitor, and the cytidine deaminase is a protein having an amino acid sequence of positions 28-164 of SEQ ID NO. 2. Further provided is the use of the fusion protein above and a biomaterial related thereto in plant single-base editing. The single-base editor can improve the efficiency of cytosine base editing and accurately mediate the base mutation of a target, and is widely applicable in the cells of maize and even other plants.

A WG-DNPs-stabilized Pickering emulsion and its application in β-carotene loading are disclosed. The emulsion is prepared by the following method: S1: Gluten protein and dextran form a covalent complex through Maillard reaction. The gluten protein complex is then prepared into a solution, and its pH is adjusted to neutral. The ionic strength of the solution is then adjusted to 15-25 mM using NaCl to obtain an intermediate solution. The intermediate solution is subjected to water bath heat treatment, ice bath cooling, and freeze drying sequentially to obtain WG-DNPs. S2: WG-DNPs are dispersed in distilled water to obtain a WG-DNPs dispersion. The WG-DNPs dispersion is mixed and homogenized with an oil phase to obtain the Pickering emulsion. This invention uses glycosylated gluten protein nanoparticles as a stabilizer for Pickering emulsions, giving the Pickering emulsions good thermal and storage stability. Furthermore, by loading β-carotene onto the Pickering emulsion stabilized by WG-DNPs, the bioavailability and digestive stability of β-carotene can be significantly improved, thus aiding in the human body's intake of β-carotene.

The invention relates to the field of biological product preparation, in particular to a preparation method of high-activity oyster-derived small molecule peptide. The method comprises the following steps: selecting fresh meat of pacific oysters or ostrea rivularis as a raw material, degreasing, adding water, crushing, filtering, sequentially carrying out compound protease and neutral protease hydrolysis, implanting a sensor and a probe in hydrolysis, monitoring in real time, and dynamically adjusting reaction conditions; adding a targeting microcapsule wrapping an ascorbic acid glutathione composite protective agent, and releasing the protective agent when a target peptide signal is detected; separating and concentrating through a gradient membrane, and purifying the target peptide by using a molecular imprinting chromatographic column; carrying out alkaline hydrolysis on enzymatic hydrolysis residues to prepare chitosan for cyclic utilization, carrying out enzymatic hydrolysis on residual residues to generate collagen peptide, treating and recycling wastewater, and recovering protease. According to the method, the technical effects that the high-activity and high-purity target peptide is prepared, the resource utilization rate is increased, the production cost is reduced, the target peptide has good oxidation resistance and biological activity, the intestinal enzyme degradation rate is reduced after glycosylation modification, and the blood half-life period is prolonged are achieved.

The invention provides an infectious bronchitis virus subunit vaccine as well as a preparation method and application thereof, and belongs to the technical field of genetic engineering vaccines. According to the chicken infectious bronchitis virus mutant protein disclosed by the invention, the amino acid sequence of the mutant protein is shown as SEQ ID NO.5. According to the avian infectious bronchitis virus subunit vaccine containing the recombinant avian infectious bronchitis virus mutant protein Kozak-IgKsp-IBV-M41-S-core-6His as an effective component, the glycosylation level of the vaccine is relatively high, the expression level is relatively stable, the virus return risk of a live vaccine does not exist, the safety is high, large-scale industrial preparation can be achieved, and the vaccine has good application prospects. The cost is low.

The present application provides a recombinant fusion protein comprising a human activin receptor 2A extracellular domain optionally fused to an immunoglobulin heavy chain constant region via a linker wherein the human ACVR2A extracellular domain comprises a mutation from Asn (N) to Ala (A) at a site corresponding to position 24 of the sequence as shown in SEQ ID NO: 1 to remove glycosylation sites.

The invention relates to the field of protein, in particular to a preparation method of recombinant human albumin and a product thereof. The preparation method comprises the following steps: constructing recombinant engineering bacteria which can silence or weaken the expression of one or more genes of PEP4, YPS1, MKC7, PRC1 and PRB1 through a gene editing technology while expressing recombinant human albumin, and silence or weaken the expression of one or more genes of PMT1, PMT2 and PMT4 at the same time; and then, carrying out low O-glycosylation fermentation culture on the obtained engineering bacteria, and carrying out separation and purification to obtain a high-purity recombinant human albumin product. According to the present invention, the protein degradation and the O-glycosylation pathway are cooperatively regulated, and the specific fermentation process is combined, such that the yield of the obtained recombinant human albumin is significantly improved, the characteristics of low immunogenicity and low glycosylation level are provided, and the performance optimization and the clinical application expansion of the recombinant human albumin product can be significantly promoted.

The invention discloses a substance composition. The present invention relates to a conjugate comprising a deglycosylated IgA-binding moiety, a cell receptor-binding moiety that binds to a hepatocyte or other degraded cell of a patient or subject through an asialoglycoprotein receptor (ASGPR) on the surface of the hepatocyte or other degraded cell, and optionally a linker moiety that links the deglycosylated IgA-binding moiety and the cell receptor-binding moiety, wherein the composition of matter can be used to remove galactose deficient IgA1 in a patient or subject.

The present disclosure relates to a recombinant cell capable of producing one or more mogroside precursors and / or one or more mogrosides in a culture medium, wherein the cell has been modified to result in the absence of a polypeptide capable of deglycosylating the mogroside product. Methods for producing one or more mogroside precursors and / or one or more mogrosides in a culture medium using such recombinant cells result in increased mogroside yield.

The invention discloses a high-efficiency wide-targeting-range C-to-G double-enzyme synergistic base editor and application thereof, and belongs to the technical field of gene editing. The editor is a fusion protein comprising a Cas protein having reduced or lost endonuclease activity, a cytosine deaminase (CDA), and a cytosine DNA glycosylase (CDG). In order to solve the problems that an existing C-to-G editor is low in efficiency and limited in targeting range, the C-to-G editor synergistically and efficiently generates a base removal (AP) site on a target DNA through the dual effects of CDA and CDG, so that C-to-G base transversion is promoted. According to the editor, the C-to-G editing efficiency is remarkably improved, an editing window can be effectively expanded or moved, the targeting flexibility is greatly enhanced, meanwhile, high genome specificity is kept, and the editor shows strong application potential in various organisms such as yeast and plants.

The invention discloses a genetically engineered bacterium for biosynthesis of gastrodin as well as a construction method and application of the genetically engineered bacterium. According to the genetically engineered bacterium, through overexpression of sucrose permease CscB derived from escherichia coli W, sucrose phosphorylase Basp of bifidobacterium adolescentis, uridine triphosphoryl-glucose-1-phosphate uridine acyl transferase UgpA of bifidobacterium bifidum and UDP-glycosyl transferase RsUGT of hedyotis diffusa, an exogenous path for synthesizing UDP-glucose from sucrose is constructed in a cell, and the UDP-glucose is synthesized into UDP-glucose. And the glycosylation capability of the gastrodin precursor on hydroxybenzyl alcohol is enhanced. The invention also provides a construction method of the genetically engineered bacterium and a method for synthesizing gastrodin through whole-cell catalysis by using the strain and taking p-hydroxybenzyl alcohol and cane sugar as substrates. The genetically engineered bacterium is high in gastrodin synthesis efficiency, the molar conversion rate can reach 97.8%, the highest yield reaches 3.61 g / L, and a new green manufacturing scheme is provided for solving the problems that a traditional gastrodin production method is low in efficiency, high in cost, large in pollution and the like.

The invention discloses a long-acting pellet suitable for gastric absorption and a preparation method of the long-acting pellet. The long-acting pellet is prepared from the following components in parts by mass: 0.01-1 part of a medicine, 1-2.5 parts of a filler, 0.2-0.7 part of a modified pore-foaming agent mixture, 1-2.5 parts of an improved adhesive mixture and 0.1-0.7 part of an improved sonokinetic response agent. Wherein the modified pore-foaming agent mixture is prepared from a modified pore-foaming agent and glycosylated saponin, the modified pore-foaming agent is prepared by mixing a pore-foaming agent and seleno-amino acid according to a mass ratio of 4: 1, the improved adhesive is mixed with the adhesive through BHP-SH, and ionic crosslinking is performed by using CaCl2 to form a covalent ion dual network, so that the stomach adhesiveness is enhanced; the sonokinetic response agent is improved by the coated poria cocos extract, and the long-acting pellet is prepared by adopting a wet granulation method or a fluidized bed method, has the characteristics of slow release, long acting, targeted stomach absorption and responsive drug release, and is suitable for treating stomach diseases such as gastritis.

The invention relates to the technical field of biology, in particular to a phloretin-O-monoglucoside glycosyl transferase protein DoUGT019 in dendrobium officinale as well as an encoding gene and application thereof, and discloses a phloretin-O-monoglucoside glycosyl transferase protein with an amino acid sequence as shown in SEQ ID NO: 1, which can be used for preparing a glycosyl transferase protein with an amino acid sequence as shown in SEQ ID NO: 1 in the presence of a UDP-glucose donor. The method has the advantages that the method is simple and convenient to operate and can catalyze O-glycosylation of phloretin A ring 2 '-OH, 4'-OH and B ring 4-OH, three high-value monoglucosides, namely phlorizin, trilobatin and phloretin-4-O-glucoside, are synchronously generated, multi-product synthesis can be realized without synergy of various enzymes, the process is greatly simplified, and the use cost of enzyme preparations is reduced. Meanwhile, discovery of the protein reveals a unique phloretin glycosylation metabolic pathway of dendrobium plants, and a cloning and functional verification system of the protein can also be used as a general technical template for research of similar glycosyltransferase to promote technical iteration and theoretical development in the field of glycosylation biosynthesis.

Described herein is a method of diagnosing Lyme disease in a subject. The method includes determining a glycosylation profile of a protein whose glycosylation profile is associated with Lyme disease in a subject, and comparing the glycosylation profile of the protein with a predetermined glycosylation profile of the protein indicating free of Lyme disease or a predetermined glycosylation profile of the protein indicating Lyme disease. Further described herein is a method of treating and / or ameliorating Lyme disease in a subject. The method includes diagnosing Lyme disease in a subject and, if the subject is diagnosed to have Lyme disease, administering to the subject an effective amount of compound effective for treating Lyme disease. Further described herein is a method of evaluating a treatment for Lyme disease. The method includes comparing a glycosylation profile of the patient with glycosylation profiles associated with successful / unsuccessful treatments.

The application discloses a chemical synthesis method of hydroxytyrosol glucoside. The method uses hydroxytyrosol as a starting material, and acetyl protection, glycosylation, hydrolysis and other steps are performed to prepare the hydroxytyrosol glucoside. The synthesis method of the hydroxytyrosol glucoside has the characteristics of low cost, simple process and industrialization.

The invention belongs to the technical field of biological medicine, and particularly relates to a reagent for detecting glycosylation modified RNA and application of the reagent in lung cancer metastasis prediction. According to the invention, glycosylation modification after RNA transcription is associated with the important pathological process of lung cancer metastasis for the first time, and a new theoretical basis and target are provided for diagnosis and treatment of lung cancer metastasis. In the prior art, the expression levels of genes and proteins are mainly concerned, and the invention goes deep into the RNA modification level and provides deeper and more accurate molecular information. And secondly, by detecting the glycosylation modification level of the LADENI, not only the expression quantity of the LADENI, the specificity and sensitivity of the LADENI as a biomarker are improved. The modification is dynamic and closely related to the function, so that the metastasis potential of the tumor cells can be reflected more accurately.

The present invention relates to surface-functionalized extracellular vehicles. Specifically, the present invention relates to exosomes surface-functionalized with lactosylated polyetheneimine (PEI-LA), such surface-functionalized exosomes as drug delivery vehicles, 5 compositions comprising a therapeutic agent encapsulated within such exosomes, methods of producing such exosomes and compositions thereof, as well as methods of delivering such exosomes and compositions to liver.

The invention relates to the technical field of biological catalysis engineering, in particular to a method for improving the solubility of stevioside Reb M and Reb D through enzyme catalysis modification, which comprises the following steps: dissolving Reb M and Reb D with the purity of more than or equal to 90% in a buffer solution with the pH value of 4.0-8.0, adding a non-starch glycosyl donor and composite glycosyl transferase according to the enzyme-substrate mass ratio of 0.05-0.5, and optimizing the enzyme addition sequence to realize specific site modification; reacting for 6-24 hours under the conditions that the pH is 5.5-6.0 and the temperature is 60-85 DEG C, and controlling the proportion of DP2-3 to be 60-80%; hPLC sampling is carried out every 4-6 hours, and the unreacted substrate is less than or equal to 20%; the solubility of the product is greater than or equal to 25g / L, and the sweet taste of the product is pure. According to the method, the solubility of Reb M / Reb D is improved, the structure of a directional glycosylation controlled product is realized, and pure sweetness is reserved; the reaction is mild and controllable, enzyme inactivation is simple and free of residues, industrialization is easy, and stevioside application upgrading is promoted.

The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to large-scale production of therapeutic molecules containing such variant Fc.

The application discloses a mycobacterium maltose transferase Co GlgE and an encoding gene and application thereof.The maltose transferase Co The amino acid sequence of the GlgE is shown as SEQ ID NO.1.The application discloses a maltose transferase Corallococcus derived from mycobacterium sp.EGB Co GlgE, which can disperse maltoligosaccharide with a polymerization degree (DP) X into products with a DP of X ± 2n (X ≥ 3). Co The GlgE has glycosylation modification effects on alpha-arbutin and beta-arbutin, the biological activity of the modified arbutin is significantly improved, and the application value of the arbutin as an additive of whitening skin care products is improved.

The present application relates to a kind of hAAG photoelectrochemical detection method based on sulfur vacancy engineering, belong to analytical detection technical field.The present application will prepare hairpin structure DNA to single-stranded DNA, sequentially join different concentrations of human alkyladenine DNA glycosylase (hAAG), endonuclease IV, exonuclease I and its reaction buffer;Dopamine solution is added to reaction, and the enzymatic reaction system of hAAG is obtained;CdZnS modified electrode is immersed in enzymatic reaction product solution and reacts, so that dopamine and zinc atom on the surface of CdZnS are combined by ortho-hydroxy coordination, and sulfur vacancy is induced to generate;Photoelectrochemical test is carried out to CdZnS modified electrode, the photocurrent signal is detected, the linear relationship between photocurrent signal and hAAG concentration is established, and the quantitative detection of hAAG is realized.The present application not only provides efficient strategy for hAAG detection, but also provides new ideas for performance optimization of sulfide-based photoelectrochemical device.

This invention relates to the field of biomedical technology, providing the application of glycoprotein tumor biomarkers in the preparation of cancer diagnostic reagents. The glycoprotein tumor biomarker is a CLU_N_291_HexNAc(4)Hex(5) site-specific glycosylation modification. This invention utilizes CLU_N_291_HexNAc(4)Hex(5) site-specific glycosylation modification as a pan-cancer biomarker, combining it with existing conventional tumor markers (CEA, CA19-9, CA50, CA242, CA72-4, CA125, CA15-3, AFP, SCC, CYFRA21-1, PROGRP, NSE, HE-4, or PSA) for early cancer screening, assessment, diagnosis, postoperative monitoring, and / or prognostic analysis, particularly for the diagnosis of pancreatic cancer, cholangiocarcinoma, gastric cancer, lung cancer, breast cancer, or ovarian cancer.

The present application belongs to the technical field of biological medicine, and particularly relates to a thiol phenylboronic acid mediated nano-enzyme immunochromatography reagent and application thereof. The present application utilizes the broad-spectrum binding ability of MPBA to the glycosylated molecules on the surface of pathogens, and combines the colorimetric catalytic double enhancement effect of the virus-like biomimetic magnetic nano-enzyme (FeAu@AuIr), to improve the detection sensitivity. The probe takes Fe3O4 magnetic nanoparticles as the core, and sequentially loads large-diameter gold nanoparticles (Au) and gold-iridium alloy (AuIr) with high catalytic activity, to enhance the pathogen capture capacity and signal amplification effect. Combined with the antibody modified immunochromatography strip, Streptococcus pneumoniae, Pseudomonas aeruginosa and SARS-CoV-2 can be simultaneously detected, and the detection sensitivity is greatly improved. Through verification of 170 clinical samples, the present application has good application prospect in on-site rapid detection, and provides an efficient and low-cost solution for precise screening of respiratory tract infectious pathogens.

The present application relates to the technical field of medicine, and provides a kind of haena polysaccharide and its preparation method and application and target endogenous coagulation pathway anticoagulant and / or antithrombotic drug.The haena polysaccharide provided by the present application is fucosylated chondroitin sulfate polysaccharide, the weight average molecular weight is 9-13 million, the molar ratio of glucuronic acid, N-acetylglucosamine and fucose is 1:0.8-1.2:0.5-0.8, and the mass percentage content of sulfate group is 25-40%.The haena polysaccharide provided by the present application can target endogenous coagulation pathway terminal rate-limiting enzyme (iFXase), and has no obvious effect on coagulation factors in other coagulation pathways, realizes the effect of anticoagulation and non-hemorrhage, and can be widely applied in acute and recovery period treatment of ischemic stroke, solves the safety problem of using anticoagulant and antithrombotic drug for clinical ischemic stroke patients, and opens up a new field of research and development of target endogenous coagulation pathway rate-limiting enzyme anticoagulant drug.

The invention belongs to the technical field of medicines, and relates to an application of a pharmaceutical composition in preparation of medicines for preventing and / or treating type II diabetes mellitus. The invention provides an application of a pharmaceutical composition in preparation of a medicine for preventing and / or treating type II diabetes mellitus. The pharmaceutical composition comprises the following components: ginsenoside Rk1, ginsenoside Rg5, ginsenoside Rg3, ginsenoside Rh4, ginsenoside Rk3, a ginseng ethanol-water extract and a pharmaceutically acceptable carrier. The pharmaceutical composition component provided by the invention can effectively reduce blood sugar and / or reduce the glycosylated hemoglobin level, and prevent and / or treat type II diabetes mellitus.

The application discloses an antibody glycosylation modification regulation method, device and application, relates to the technical field of biopharmaceuticals and protein engineering, and realizes directional regulation of modification types, modification sites and modification proportions of N-glycan and O-glycan of the antibody through three core processes of constructing a glycosyltransferase engineering strain, optimizing a fermentation culture system and precisely regulating modification reaction conditions; solves the technical problems of low modification efficiency, poor specificity and insufficient product uniformity in the existing modification method, can improve the target glycan modification proportion to more than 90%, the modification product purity is greater than or equal to 98%, is suitable for glycosylation modification optimization of therapeutic monoclonal antibodies, bispecific antibodies and antibody drug conjugates, significantly improves the biological activity and pharmacokinetic performance of the antibody, wherein the ADCC activity is improved by 3-5 times, and the CDC activity is improved by 2-4 times, and has the advantages of strong controllability, good adaptability to large-scale production and high cost-effectiveness.